Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RENEW-SHCS: A Phase 1 Open-label Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Env Protein BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted, in ARV-treated Adults Living With HIV Enrolled in the SHCS and to Restimulate and Newly Prime Antibody Responses.

NCT07769983 is registered in ClinicalTrials.gov with University of Zurich as lead sponsor.

NCT NCT07769983
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07769983 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RENEW-SHCS: A Phase 1 Open-label Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Env Protein BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted, in ARV-treated Adults Living With HIV Enrolled in the SHCS and to Restimulate and Newly Prime Antibody Responses.
Lead sponsor
University of Zurich
Phase
Phase 1
Overall status
Enrolling by invitation
Start date
February 25, 2025
Completion date
March 31, 2028
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

antibody response, people living with hiv